In the last decade we have witnessed tremendous advances in our understanding of the landscape of the molecular alterations that underpin many of the most prevalent cancers, in the use of automated high-throughput platforms for high-throughput drug screens in cancer cells, in the creation of more clinically relevant cancer cell models, and lastly in the development of more useful computational approaches in the pursuit of biomarkers of drug response. Separately, each of these improvements will undoubtedly lead to improvements in the treatment of cancer patients but to fulfill the promise of truly personalized cancer medicine, we must bring these disciplines together in a truly multidisciplinary fashion.

中文翻译：

---

高通量癌细胞药物筛选对治疗性生物标志物的追求

在过去的十年中，我们见证了对自动化的高通量平台在癌细胞中进行高通量药物筛查的理解，从而了解了许多最普遍的癌症所依据的分子变化的格局，从而取得了长足的进步临床上更具相关性的癌细胞模型的建立，以及最后在追求药物反应生物标记物的更有用的计算方法的开发中。单独地，这些改进中的每一个无疑都将导致癌症患者治疗的改进，但是要实现真正个性化的癌症医学的承诺，我们必须以真正的多学科方式将这些学科结合在一起。